All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The presence of Minimal Residual Disease (MRD) before allogeneic Stem Cell Transplantation (SCT) has been shown to be associated with poor outcomes in patients with Acute Myeloid Leukemia (AML).1 Multicolor Flow Cytometry (MFC) is recognized as a reliable tool for evaluation of MRD. Furthermore, Wilms Tumor 1 (WT1) gene expression is the most standardized molecular MRD marker in AML.
In a Letter to the Editor of Haematologica on 11th May 2017, Fabio Guolo, University of Genoa, Genoa, and colleagues discuss results from their retrospective study which analyzed the role of pre-transplant combined MFC-molecular MRD assessment as a predictor of post-transplant relapse risk.2,3
WT1 gene expression and MRD evaluation by MFC was analyzed in bone marrow samples from 224 consecutive AML patients who received allogenic-SCT in either First or Second Complete Remission (CR1/2) at the IRCCS AOU San Martino-IST, University of Genoa between January 2004 and January 2014.
In summation, combined molecular (WT1- based) and MFC assessment of pre-transplant MRD can accurately predict relapse risk in AML patients.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox